Skip to main content
Neuropsychopharmacology logoLink to Neuropsychopharmacology
. 2020 May 6;45(8):1405. doi: 10.1038/s41386-020-0699-7

Correction: Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression

Cristan A Farmer 1, Jessica R Gilbert 1, Ruin Moaddel 2, Jomy George 3, Lilian Adeojo 3, Jacqueline Lovett 2, Allison C Nugent 1,4, Bashkim Kadriu 1, Peixiong Yuan 1, Todd D Gould 5,6, Lawrence T Park 1, Carlos A Zarate Jr 1,
PMCID: PMC7414102  PMID: 32376872

Correction to: Neuropsychopharmacology 10.1038/s41386-020-0663-6, published online 06 April 2020

Following the publication of this article, the authors have noticed that the definition of response in the legend of Fig. 2 of the original manuscript was incorrect. The corrected text is as follows:

Relationship between (2S,6S;2R,6R)-hydroxynorketamine (HNK) Cmax and antidepressant response to ketamine. The figure plots the difference in MADRS total score between ketamine and placebo arms (response; ketamine minus placebo) by (2S,6S;2R,6R)-HNK Cmax, at each timepoint. The slope for each relationship (with 95% confidence interval) is provided (see also Supplementary Table S2). Increased (2S,6S;2R,6R)-HNK maximum concentration was associated with less clinical response, but this relationship was most robust at later timepoints. MADRS Montgomery-Asberg Depression Rating Scale.

The scientific conclusions of this paper have not been affected.


Articles from Neuropsychopharmacology are provided here courtesy of Nature Publishing Group

RESOURCES